NCT05245084View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

June 6, 2022

Study Completion Date

June 20, 2022

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-386(3)

QD, PO

DRUG

D013, D326, D337

QD, PO

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY